Blair William & Co. IL Sells 2,292 Shares of Catalent, Inc. (NYSE:CTLT)

Blair William & Co. IL reduced its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 5.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 39,706 shares of the company’s stock after selling 2,292 shares during the quarter. Blair William & Co. IL’s holdings in Catalent were worth $2,233,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of CTLT. UBS Group AG boosted its holdings in shares of Catalent by 2.6% in the 4th quarter. UBS Group AG now owns 726,563 shares of the company’s stock worth $32,644,000 after buying an additional 18,752 shares during the last quarter. Gamco Investors INC. ET AL boosted its stake in Catalent by 403.3% in the first quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock valued at $1,428,000 after acquiring an additional 20,273 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Catalent by 2,792.9% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock valued at $29,150,000 after acquiring an additional 498,540 shares during the period. UniSuper Management Pty Ltd raised its holdings in shares of Catalent by 509.4% in the 1st quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company’s stock worth $1,028,000 after purchasing an additional 15,217 shares during the period. Finally, Swedbank AB purchased a new position in Catalent in the first quarter valued at approximately $1,659,000.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CTLT. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. Barclays increased their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. Finally, StockNews.com assumed coverage on shares of Catalent in a research report on Wednesday, September 18th. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $58.08.

Insider Buying and Selling

In related news, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the sale, the senior vice president now owns 39,635 shares of the company’s stock, valued at $2,360,264.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the sale, the senior vice president now owns 39,635 shares in the company, valued at approximately $2,360,264.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Ricky Hopson sold 662 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the sale, the insider now owns 29,974 shares in the company, valued at approximately $1,785,251.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,409 shares of company stock valued at $782,923. Company insiders own 0.31% of the company’s stock.

Catalent Trading Down 0.2 %

Shares of CTLT opened at $60.00 on Monday. Catalent, Inc. has a twelve month low of $31.80 and a twelve month high of $61.20. The stock has a market cap of $10.86 billion, a PE ratio of -9.84, a P/E/G ratio of 1.88 and a beta of 1.15. The company has a quick ratio of 1.77, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. The business’s 50-day moving average price is $59.48 and its 200-day moving average price is $57.22.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.